Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-FLOR: Golcadomide + Rituximab +/- Nivolumab in First-Line Follicular Lymphoma
NCT05788081Phase 2Active, not recruiting
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Aug 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of golcadomide in follicular lymphoma (FL) (2 arms), sponsored by Olivia Newton-John Cancer Research Institute. Primary endpoint: Complete Metabolic Response at 44 weeks. Started Aug 2023; status: active, not recruiting.
02
Drugs
golcadomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05788081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788081.